Once again, Massachusetts is trying to find a way to lower its Medicaid prescription drug bill, but this time, state officials hope to negotiate supplemental rebates — and potentially cite drug makers for violating consumer protection laws if they fail to play ball.

The effort is the latest by state lawmakers to find a way to constrain drug spending, an issue that is stretching budgets across the U.S. amid rising prices, especially for some newer medicines. The move also comes after Massachusetts officials last year failed to win federal government approval to exclude some drugs from the state Medicaid program, which was an earlier attempt to reduce costs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy